Clinical Practice Surveillance of the Use of Herceptin in Patients With HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES)

Trial Profile

Clinical Practice Surveillance of the Use of Herceptin in Patients With HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES)

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms HERMES
  • Sponsors Roche
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 10 Jun 2017 Biomarkers information updated
    • 21 Mar 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top